Noom Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

What Is Noom and How Does Its Prescribing Model Work?

Noom operates as a two-component platform: a psychology-based weight-loss coaching app and a separate telehealth prescribing service called Noom Med, launched in 2023. The app uses cognitive behavioral techniques to guide food logging and habit change. Noom Med adds asynchronous clinician consultations that can result in GLP-1 prescriptions, primarily semaglutide or tirzepatide, depending on formulary availability.

The App-Only Coaching Arm

The behavioral coaching component has the longest published track record. A 2016 study published in the Journal of Medical Internet Research (Chin et al., N=36,174) found that users who engaged with the program for at least 16 weeks lost a mean of 7.5% of their initial body weight [1]. A separate analysis of 3.7 million Noom users published by the company's own research team in Scientific Reports in 2021 reported a mean weight loss of approximately 5.1% over 52 weeks among completers, with a significant dropout-related limitation the authors acknowledged directly [2].

Those figures sit at or just above the American Heart Association's threshold of 5% weight loss as the minimum clinically meaningful reduction for cardiometabolic risk [3].

The Noom Med GLP-1 Arm

Noom Med allows patients with a BMI of 30 or higher (or BMI <30 with a qualifying comorbidity) to receive a GLP-1 prescription after an asynchronous intake. The consultation process is conducted via questionnaire and messaging rather than synchronous video, which is a common telehealth model but one that limits the depth of a prescriber's assessment compared to an in-person visit.

No peer-reviewed clinical trial has reported outcome data specific to Noom Med GLP-1 patients. The absence of that data is the most consequential gap in evaluating this platform.

How Do Noom's Published Outcomes Compare to Clinical Trial Benchmarks?

App-based weight loss of 5 to 7 percent is clinically real but substantially below what FDA-approved GLP-1 agonists produce in controlled trials. Understanding that gap helps set realistic expectations.

Semaglutide and Tirzepatide Trial Benchmarks

In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001) [4]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced a mean weight loss of 20.9% at 72 weeks versus 3.1% with placebo [5].

Both trials enrolled patients with structured follow-up, lifestyle counseling built into the protocol, and close monitoring for adverse events. Real-world outcomes in telehealth settings frequently fall below trial results because adherence, dose escalation, and follow-up are less structured.

What Real-World Telehealth Data Shows

A 2023 analysis in Obesity (Almandoz et al.) examined real-world semaglutide outcomes across multiple prescribing settings and found that patients who received the drug without intensive lifestyle support lost a mean of approximately 8 to 10% body weight at 52 weeks, compared to 12 to 15% in settings with structured lifestyle programming [6]. Noom's behavioral coaching component could theoretically narrow that gap, but no published data confirms whether Noom Med patients achieve outcomes closer to the trial arm or the unsupported-prescribing arm.

The Completer Bias Problem

The 2021 Noom app study (N=3.7 million) reported outcomes only for users who engaged for at least two weeks, and its headline figure applied to completers, not the full enrolled cohort [2]. Dropout rates in commercial weight-loss programs are high. The CDC estimates that roughly 50% of participants in commercial weight-loss programs disengage within the first six months [7]. That figure means completer-only statistics overestimate typical patient outcomes.

Is Noom Legit? Licensing, Accreditation, and Regulatory Standing

"Is Noom legit" is among the most commonly searched questions about the platform, and the answer requires separating several distinct regulatory questions.

State Medical Board Compliance

Noom Med, like all telehealth prescribers, must comply with state medical board requirements for prescribing. The Ryan Haight Online Pharmacy Consumer Protection Act requires a valid patient-provider relationship before controlled substances can be prescribed, though GLP-1 agonists are not scheduled substances and fall outside that specific requirement [8]. States individually regulate telehealth prescribing standards; some require a synchronous video visit before prescribing, while others allow asynchronous consultation. Noom Med's asynchronous intake model may not satisfy the more stringent synchronous-visit requirements in states such as Arkansas, Oklahoma, and West Virginia.

LegitScript Certification

LegitScript is the primary third-party certification body for online pharmacies and telehealth prescribers in the United States. As of January 2025, Noom Med does not appear in the LegitScript-certified telehealth provider database [9]. That absence does not mean Noom is operating illegally, but it does mean the platform has not undergone LegitScript's independent verification of prescribing practices, pharmacy relationships, and compliance protocols.

FDA and Compounding Considerations

FDA-approved semaglutide formulations are Ozempic (2 mg/dose injection), Wegovy (2.4 mg), and Rybelsus (oral). Compounded semaglutide is not FDA-approved and was permitted under shortage exceptions through 503A and 503B pharmacy provisions [10]. As of early 2025, the FDA removed semaglutide from its drug shortage list, which means 503A compounding pharmacies are no longer permitted to compound copies of the drug. Platforms that continue to offer compounded semaglutide after that removal face regulatory risk. Patients should confirm whether any GLP-1 prescription from Noom Med is for an FDA-approved formulation.

Noom Complaints: What Patterns Emerge?

Complaint data from the Better Business Bureau and user review aggregators surfaces recurring themes that are distinct from clinical efficacy and worth examining separately.

Billing and Cancellation Complaints

The BBB profile for Noom Inc. Reflects an A rating with accreditation, but the complaint log contains a high volume of billing-related grievances. The most common pattern involves difficulty canceling recurring subscriptions, unexpected charges after free-trial periods, and refund denials [11]. These complaints apply primarily to the coaching app subscription rather than Noom Med prescriptions.

The HealthRX clinical team uses the following four-factor framework when evaluating telehealth weight-loss platforms for patients: (1) published peer-reviewed outcome data with intention-to-treat analysis, not completer-only analysis; (2) LegitScript or equivalent third-party accreditation of the prescribing arm; (3) synchronous prescriber contact available before and during GLP-1 initiation; and (4) transparent formulary disclosure specifying whether prescriptions are for FDA-approved branded medications or compounded alternatives.

Clinical Care Quality Complaints

A secondary pattern in user feedback involves the asynchronous nature of clinical consultations. Patients report that their intake questionnaire was reviewed and a prescription was issued without a phone or video call. While this is legal in most states, it raises questions about whether prescribers can adequately screen for GLP-1 contraindications, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or pancreatitis, through a questionnaire alone [12].

The FDA labeling for semaglutide (Wegovy) carries a boxed warning for thyroid C-cell tumors and states that the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma [10]. A text-only intake may not reliably elicit that history compared to a direct clinical interview.

Medication Supply and Formulary Transparency

Some Noom Med users report receiving compounded semaglutide without being clearly informed that it was not the FDA-approved Wegovy formulation. Supply chain issues for branded GLP-1 products have affected all telehealth platforms since 2022, but transparency in communicating the distinction to patients is a quality indicator. Patients prescribed compounded semaglutide are not covered by Novo Nordisk's patient assistance programs and cannot access the branded drug's pharmacovigilance data.

What Clinical Guidelines Say About Telehealth GLP-1 Prescribing

No single federal guideline governs telehealth GLP-1 prescribing specifically, but several bodies have addressed the standards that apply.

Endocrine Society Guidance

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends that GLP-1 agonists be prescribed as part of a comprehensive weight management program that includes dietary counseling, physical activity guidance, and behavioral support [13]. Noom's app-based behavioral component could satisfy that recommendation in principle, but the guideline specifies that the behavioral support should be ongoing and clinician-monitored rather than algorithm-driven.

AHA/ACC Obesity Guidelines

The 2022 AHA/ACC/AAPA/ABC/ACPM/AGS/APhA/ASPC/NMA/PCNA guideline on cardiovascular risk reduction through lifestyle and pharmacological interventions states that weight-loss medications should be used alongside, not instead of, lifestyle modification [3]. The combined Noom app plus Noom Med model aligns with that architecture on paper. Whether execution matches the design depends on variables that no published outcome study has yet measured.

USPSTF Recommendations

The U.S. Preventive Services Task Force recommends offering or referring adults with obesity to intensive multicomponent behavioral intervention (grade B recommendation) [14]. "Intensive" is defined as 12 or more sessions in the first year. Noom's coaching model can deliver that session density through the app, but human coach availability varies by subscription tier.

Key Evidence Gaps That Patients and Clinicians Should Know

The evidence base for Noom as a combined behavioral-plus-GLP-1 platform has four specific gaps that should inform prescribing and enrollment decisions.

No RCT for Noom Med GLP-1 Outcomes

No randomized controlled trial has compared Noom Med GLP-1 patients to a control group. All available data comes from the app-only studies or from independent GLP-1 trials conducted outside the Noom context. This gap is not unique to Noom; most telehealth GLP-1 platforms lack platform-specific RCT data. The gap means prescribers cannot cite Noom-specific efficacy evidence when recommending the platform.

No Intention-to-Treat Analysis Published

The 2021 Scientific Reports study used a completer cohort, not an intention-to-treat population [2]. Intention-to-treat analysis is the standard required by FDA for drug approval trials because it reflects real-world dropout rates. A completer-only figure of 5.1% weight loss in 52 weeks almost certainly overstates what the average enrolled user achieves.

No Long-Term Cardiovascular Outcome Data

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease [15]. That finding applies to Wegovy specifically as prescribed in a rigorous trial setting. No data exists showing whether Noom Med patients achieve equivalent cardiovascular risk reduction, given the differences in follow-up intensity and dose adherence monitoring.

No Head-to-Head Comparison With Competitors

No published study has compared Noom Med outcomes directly to those of comparable telehealth GLP-1 platforms. Independent head-to-head data would meaningfully improve the ability to recommend one platform over another.

Practical Guidance for Patients Considering Noom Med

Patients who are weighing Noom Med as a GLP-1 access point should ask four direct questions before enrolling.

First, ask whether the GLP-1 prescription will be for an FDA-approved branded medication (Wegovy or Ozempic) or a compounded alternative, and what the prescriber's policy is if the branded medication becomes unavailable.

Second, ask whether a synchronous video or telephone consultation with a licensed prescriber is available before the first prescription is issued.

Third, ask what monitoring protocol exists for dose escalation. The Wegovy prescribing information recommends a specific four-step dose escalation over 16 weeks (0.25 mg, 0.5 mg, 1.0 mg, and 1.7 mg before reaching the 2.4 mg maintenance dose) to minimize gastrointestinal adverse effects [10]. Confirm that the platform follows that schedule.

Fourth, confirm which state the prescribing clinician is licensed in and whether that state's telehealth prescribing rules permit asynchronous-only consultations for new patients.